172 related articles for article (PubMed ID: 30809676)
1. The rise and fall of long-latency Plasmodium vivax.
White NJ
Trans R Soc Trop Med Hyg; 2019 Apr; 113(4):163-168. PubMed ID: 30809676
[TBL] [Abstract][Full Text] [Related]
2. Management of relapsing Plasmodium vivax malaria.
Chu CS; White NJ
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):885-900. PubMed ID: 27530139
[TBL] [Abstract][Full Text] [Related]
3. [Role of primaquine in malaria control and elimination in French-speaking Africa].
Briolant S; Pradines B; Basco LK
Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
[TBL] [Abstract][Full Text] [Related]
4. Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.
Ebstie YA; Abay SM; Tadesse WT; Ejigu DA
Drug Des Devel Ther; 2016; 10():2387-99. PubMed ID: 27528800
[TBL] [Abstract][Full Text] [Related]
5. Plasmodium vivax in the Era of the Shrinking P. falciparum Map.
Price RN; Commons RJ; Battle KE; Thriemer K; Mendis K
Trends Parasitol; 2020 Jun; 36(6):560-570. PubMed ID: 32407682
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
Smoak BL; DeFraites RF; Magill AJ; Kain KC; Wellde BT
Am J Trop Med Hyg; 1997 Feb; 56(2):231-4. PubMed ID: 9080885
[TBL] [Abstract][Full Text] [Related]
7. Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis.
Shimizu S; Kikuchi T; Koga M; Kato Y; Matsuoka H; Maruyama H; Kimura M;
Travel Med Infect Dis; 2015; 13(3):235-40. PubMed ID: 25482427
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.
Kristensen KL; Dragsted UB
Scand J Infect Dis; 2014 Jan; 46(1):63-5. PubMed ID: 23957539
[TBL] [Abstract][Full Text] [Related]
9. Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
Kim JR; Nandy A; Maji AK; Addy M; Dondorp AM; Day NP; Pukrittayakamee S; White NJ; Imwong M
PLoS One; 2012; 7(7):e39645. PubMed ID: 22808048
[TBL] [Abstract][Full Text] [Related]
10. Control and elimination of Plasmodium vivax.
Shanks GD
Adv Parasitol; 2012; 80():301-41. PubMed ID: 23199491
[TBL] [Abstract][Full Text] [Related]
11. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
12. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.
Commons RJ; Simpson JA; Thriemer K; Hossain MS; Douglas NM; Humphreys GS; Sibley CH; Guerin PJ; Price RN
Lancet Infect Dis; 2019 Jan; 19(1):91-101. PubMed ID: 30587297
[TBL] [Abstract][Full Text] [Related]
13. Relapse.
White NJ; Imwong M
Adv Parasitol; 2012; 80():113-50. PubMed ID: 23199487
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium vivax treatments: what are we looking for?
Price RN; Douglas NM; Anstey NM; von Seidlein L
Curr Opin Infect Dis; 2011 Dec; 24(6):578-85. PubMed ID: 21986614
[TBL] [Abstract][Full Text] [Related]
15. Status of Plasmodium vivax malaria in the Republic of Korea, 2008-2009: decrease followed by resurgence.
Yeom JS; Jun G; Kim JY; Lee WJ; Shin EH; Chang KS; Bang JH; Oh S; Kang JY; Park JW
Trans R Soc Trop Med Hyg; 2012 Jul; 106(7):429-36. PubMed ID: 22560604
[TBL] [Abstract][Full Text] [Related]
16. Imported tertian malaria resistant to primaquine.
Na DJ; Han JD; Cha DY; Song IK; Choi HW; Chung EA; Park CW; Choi JS
Korean J Intern Med; 1999 Jul; 14(2):86-9. PubMed ID: 10461431
[TBL] [Abstract][Full Text] [Related]
17. The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India.
Roy M; Bouma MJ; Ionides EL; Dhiman RC; Pascual M
PLoS Negl Trop Dis; 2013; 7(1):e1979. PubMed ID: 23326611
[TBL] [Abstract][Full Text] [Related]
18. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.
Goller JL; Jolley D; Ringwald P; Biggs BA
Am J Trop Med Hyg; 2007 Feb; 76(2):203-7. PubMed ID: 17297026
[TBL] [Abstract][Full Text] [Related]
19. Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala.
Signorini L; Matteelli A; Castelnuovo F; Castelli F; Oladeji O; Carosi G
Am J Trop Med Hyg; 1996 Nov; 55(5):472-3. PubMed ID: 8940974
[TBL] [Abstract][Full Text] [Related]
20. Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.
Campo B; Vandal O; Wesche DL; Burrows JN
Pathog Glob Health; 2015 May; 109(3):107-22. PubMed ID: 25891812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
